CN116507325A - 用于治疗tau蛋白病的方法 - Google Patents

用于治疗tau蛋白病的方法 Download PDF

Info

Publication number
CN116507325A
CN116507325A CN202180028457.1A CN202180028457A CN116507325A CN 116507325 A CN116507325 A CN 116507325A CN 202180028457 A CN202180028457 A CN 202180028457A CN 116507325 A CN116507325 A CN 116507325A
Authority
CN
China
Prior art keywords
deuterated
optionally substituted
acid
ester
pufa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028457.1A
Other languages
English (en)
Chinese (zh)
Inventor
米哈伊尔·谢尔盖维奇·什彻皮诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiojiwa Co ltd
Original Assignee
Baiojiwa Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiojiwa Co ltd filed Critical Baiojiwa Co ltd
Publication of CN116507325A publication Critical patent/CN116507325A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180028457.1A 2020-02-14 2021-02-12 用于治疗tau蛋白病的方法 Pending CN116507325A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976958P 2020-02-14 2020-02-14
US62/976,958 2020-02-14
PCT/US2021/017981 WO2021163580A1 (en) 2020-02-14 2021-02-12 Methods for treating tauopathy

Publications (1)

Publication Number Publication Date
CN116507325A true CN116507325A (zh) 2023-07-28

Family

ID=77273602

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028457.1A Pending CN116507325A (zh) 2020-02-14 2021-02-12 用于治疗tau蛋白病的方法

Country Status (9)

Country Link
US (2) US20210251933A1 (https=)
EP (1) EP4103169A4 (https=)
JP (2) JP2023513901A (https=)
KR (1) KR20220140808A (https=)
CN (1) CN116507325A (https=)
AU (1) AU2021220981A1 (https=)
CA (1) CA3171330A1 (https=)
IL (1) IL295512A (https=)
WO (1) WO2021163580A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170134A2 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
US11491130B2 (en) * 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
KR20240055796A (ko) * 2021-09-03 2024-04-29 바이오지바 엘엘씨 중수소화 pufa를 이용한 세포 기능장애 및 세포 사멸의 억제를 위한 방법, 시스템 및 조성물
IL313592A (en) * 2021-12-21 2024-08-01 Biojiva Llc Methods and preparations for the treatment of inflammatory disease
WO2023192406A2 (en) * 2022-03-30 2023-10-05 Retrotope, Inc. Prophylactic methods for treating als

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20140147428A1 (en) * 2011-04-26 2014-05-29 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
EP3461479A1 (en) * 2017-09-27 2019-04-03 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
CN110167546A (zh) * 2016-11-17 2019-08-23 乐巢拓普有限公司 同位素修饰的组分及其治疗用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
JP2021527648A (ja) * 2018-06-15 2021-10-14 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の低減

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20140147428A1 (en) * 2011-04-26 2014-05-29 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
CN110167546A (zh) * 2016-11-17 2019-08-23 乐巢拓普有限公司 同位素修饰的组分及其治疗用途
EP3461479A1 (en) * 2017-09-27 2019-04-03 Julie Blivet Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMED ELHARRAM等: "Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer\'s disease", 《 FEBS J》, vol. 284, no. 23, 27 October 2017 (2017-10-27), pages 4083 - 4095 *
K. AOYAMA等: "Aging and oxidative stress in progressive supranuclear palsy", 《EUROPEAN JOURNAL OF NEUROLOGY, vol. 13, 12 January 2006 (2006-01-12), pages 89 - 92, XP072027718, DOI: 10.1111/j.1468-1331.2006.01139.x *
SOPHIA M RAEFSKY等: "Deuterated Polyunsaturated Fatty Acids Reduce Brain Lipid Peroxidation and Hippocampal Amyloid β-Peptide Levels, Without Discernable Behavioral Effects in an APP/PS1 Mutant Transgenic Mouse Model of Alzheimer\'s Disease", 《NEUROBIOL AGING》, vol. 66, 5 March 2018 (2018-03-05), pages 165 - 176, XP055835359, DOI: 10.1016/j.neurobiolaging.2018.02.024 *

Also Published As

Publication number Publication date
WO2021163580A1 (en) 2021-08-19
US20250177339A1 (en) 2025-06-05
US20210251933A1 (en) 2021-08-19
JP2023513901A (ja) 2023-04-04
CA3171330A1 (en) 2021-08-19
JP2026035680A (ja) 2026-03-04
EP4103169A1 (en) 2022-12-21
IL295512A (en) 2022-10-01
AU2021220981A1 (en) 2022-09-22
KR20220140808A (ko) 2022-10-18
EP4103169A4 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
CN116507325A (zh) 用于治疗tau蛋白病的方法
CA2840224C (en) Treatment of proteinopathies
ES2812800T3 (es) Nuevos usos terapéuticos de derivados de la bencilidenguanidina para el tratamiento de proteopatías
US9187485B2 (en) Methods and compositions for the treatment of cancer and related hyperproliferative disorders
BR122019017719B1 (pt) Inibidores de glicosilceramida sintase
ES2871416T3 (es) Inhibidores de glucosilceramida sintasa
MX2011005095A (es) Tratamiento de proteinopatias usando un inhibidor de farnesil transferasa.
ES2683184T3 (es) Inhibidores de GLyT1 para su uso en el tratamiento de trastornos hemáticos
WO2010098888A1 (en) Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
WO2008060332A2 (en) Methods for treating or reducing muscle fatigue
CN115515974B (zh) Pi4k抑制剂在细胞内蛋白错误折叠相关疾病和溶酶体贮积病中的应用
JP2012514032A (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
US12162891B2 (en) Glutamate transporter activators and methods using same
WO2023023397A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
US20170258791A1 (en) Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
US20190015472A1 (en) Compositions and methods for treating beta-amyloid related diseases
EP2522394B1 (en) Substituted phosphonates and their use decreasing amyloid aggregates
US20100331363A1 (en) Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
Tan et al. Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
HK40106579B (en) Administration and dosage of diaminophenothiazines
EP2527322A1 (en) Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses
BR112016023086B1 (pt) Composto, composição, e, uso de um composto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination